222 related articles for article (PubMed ID: 15683433)
1. Comparative study of nizatidine and famotidine for maintenance therapy of erosive esophagitis.
Hamamoto N; Hashimoto T; Adachi K; Hirakawa K; Ishihara S; Inoue H; Taniura H; Niigaki M; Sato S; Kushiyama Y; Suetsugu H; Miyake T; Kinoshita Y
J Gastroenterol Hepatol; 2005 Feb; 20(2):281-6. PubMed ID: 15683433
[TBL] [Abstract][Full Text] [Related]
2. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.
Armstrong D; Paré P; Pericak D; Pyzyk M;
Am J Gastroenterol; 2001 Oct; 96(10):2849-57. PubMed ID: 11695354
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of gastrosidine (famotidine) in the treatment of gastroesophageal reflux at the reflux esophagitis stage].
Vasil'ev IuV; Li IA
Eksp Klin Gastroenterol; 2002; (4):30-3, 131. PubMed ID: 12503271
[TBL] [Abstract][Full Text] [Related]
4. Treatment of erosive reflux oesophagitis: a double-blind multicentre trial with nizatidine 300 mg b.i.d. versus placebo.
Dobrilla G; Chilovi F; Tafner G; Vantini I; Bernardi A; Gentilini R; Fedrizzi F; Manfrini R; Steiner H; Mon M
Ital J Gastroenterol; 1992; 24(6):338-41. PubMed ID: 1515660
[TBL] [Abstract][Full Text] [Related]
5. Selection of patients for successful maintenance treatment of esophagitis with low-dose omeprazole: use of 24-hour gastric pH monitoring.
Ladas SD; Tassios PS; Raptis SA
Am J Gastroenterol; 2000 Feb; 95(2):374-80. PubMed ID: 10685738
[TBL] [Abstract][Full Text] [Related]
6. Nizatidine versus placebo in gastroesophageal reflux disease: a 12-week, multicenter, randomized, double-blind study.
Cloud ML; Offen WW; Robinson M
Am J Gastroenterol; 1991 Dec; 86(12):1735-42. PubMed ID: 1962618
[TBL] [Abstract][Full Text] [Related]
7. Preventive therapy for non-steroidal anti-inflammatory drug-induced ulcers in Japanese patients with rheumatoid arthritis: the current situation and a prospective controlled-study of the preventive effects of lansoprazole or famotidine.
Miyake K; Ueki N; Suzuki K; Shinji Y; Kusunoki M; Hiratsuka T; Nishigaki H; Tatsuguchi A; Futagami S; Wada K; Tsukui T; Nakajima A; Yoshino S; Sakamoto C
Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():67-72. PubMed ID: 15943850
[TBL] [Abstract][Full Text] [Related]
8. Famotidine in gastroesophageal reflux disease (GERD).
Wesdorp IC
Hepatogastroenterology; 1992 Feb; 39 Suppl 1():24-6. PubMed ID: 1577391
[TBL] [Abstract][Full Text] [Related]
9. Maintenance therapy for erosive esophagitis in children after healing by omeprazole: is it advisable?
Boccia G; Manguso F; Miele E; Buonavolontà R; Staiano A
Am J Gastroenterol; 2007 Jun; 102(6):1291-7. PubMed ID: 17319927
[TBL] [Abstract][Full Text] [Related]
10. Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole.
Adachi K; Hashimoto T; Komazawa Y; Mihara T; Furuta K; Fujishiro H; Ishihara S; Amano Y; Hattori S; Kinoshita Y
Dig Liver Dis; 2005 Jul; 37(7):485-90. PubMed ID: 15975534
[TBL] [Abstract][Full Text] [Related]
11. Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.
Fujiwara Y; Higuchi K; Nebiki H; Chono S; Uno H; Kitada K; Satoh H; Nakagawa K; Kobayashi K; Tominaga K; Watanabe T; Oshitani N; Arakawa T
Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():10-8. PubMed ID: 15943841
[TBL] [Abstract][Full Text] [Related]
12. The medical management of reflux esophagitis. Role of antacids and acid inhibition.
Sontag SJ
Gastroenterol Clin North Am; 1990 Sep; 19(3):683-712. PubMed ID: 1977703
[TBL] [Abstract][Full Text] [Related]
13. Treatment of childhood peptic esophagitis: a double-blind placebo-controlled trial of nizatidine.
Simeone D; Caria MC; Miele E; Staiano A
J Pediatr Gastroenterol Nutr; 1997 Jul; 25(1):51-5. PubMed ID: 9226527
[TBL] [Abstract][Full Text] [Related]
14. Is a proton pump inhibitor necessary for the treatment of lower-grade reflux esophagitis?
Soga T; Matsuura M; Kodama Y; Fujita T; Sekimoto I; Nishimura K; Yoshida S; Kutsumi H; Fujimoto S
J Gastroenterol; 1999 Aug; 34(4):435-40. PubMed ID: 10452673
[TBL] [Abstract][Full Text] [Related]
15. Nizatidine for the treatment of pediatric gastroesophageal reflux symptoms: an open-label, multiple-dose, randomized, multicenter clinical trial in 210 children.
Orenstein SR; Gremse DA; Pantaleon CD; Kling DF; Rotenberg KS
Clin Ther; 2005 Apr; 27(4):472-83. PubMed ID: 15922820
[TBL] [Abstract][Full Text] [Related]
16. [Maintenance therapy of mild form of GERD by H2 receptor antagonists].
Kurosawa S
Nihon Rinsho; 2000 Sep; 58(9):1859-64. PubMed ID: 11004816
[TBL] [Abstract][Full Text] [Related]
17. Famotidine 40mg B.I.D. in the treatment of reflux oesophagitis.
Ahmed W; Qureshi H; Alam SE; Zuberi SJ
J Pak Med Assoc; 1995 Sep; 45(9):241-3. PubMed ID: 8683830
[TBL] [Abstract][Full Text] [Related]
18. Factors predicting relapse during maintenance treatment with famotidine in patients with healed reflux esophagitis. Dutch Esophagitis Study Group.
Wesdorp IC; Dekker W; Festen HP
Clin Ther; 1997; 19(5):1048-57. PubMed ID: 9385492
[TBL] [Abstract][Full Text] [Related]
19. Impact of blockade of histamine H2 receptors on chronic heart failure revealed by retrospective and prospective randomized studies.
Kim J; Ogai A; Nakatani S; Hashimura K; Kanzaki H; Komamura K; Asakura M; Asanuma H; Kitamura S; Tomoike H; Kitakaze M
J Am Coll Cardiol; 2006 Oct; 48(7):1378-84. PubMed ID: 17010798
[TBL] [Abstract][Full Text] [Related]
20. Tolerance to H2 receptor antagonist correlates well with the decline in efficacy against gastroesophageal reflux in patients with gastroesophageal reflux disease.
Furuta K; Adachi K; Komazawa Y; Mihara T; Miki M; Azumi T; Fujisawa T; Katsube T; Kinoshita Y
J Gastroenterol Hepatol; 2006 Oct; 21(10):1581-5. PubMed ID: 16928220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
